Finanzen von enGene Therapeutics Inc (ENGN)ENGNenGene Therapeutics Inc

Evaluating the bottom line, enGene Therapeutics Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -60.50%, provide a clear picture of how effectively ENGN converts its operational activities into shareholder value.

In the context of the broader market, ENGN competes directly with industry leaders such as CBUS and TISI. With a market capitalization of $112.59M, it holds a leading position in the sector. When comparing efficiency, ENGN's gross margin of N/A stands against CBUS's 100.00% and TISI's 21.39%. Such benchmarking helps identify whether enGene Therapeutics Inc. is trading at a premium or discount relative to its financial performance.

enGene has reported consistent net losses, with a Q2 2026 net loss of $30.23 million and a gross profit of -$180,000, showing ongoing financial struggles. The company has a current ratio of 10.21, indicating good short-term liquidity, but its negative earnings and cash flow metrics raise concerns.